Adaptive Biotechnologies(ADPT) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday
BenzingaMar 21 10:29 ET
Goldman Sachs Upgrades Adaptive Biotechnologies(ADPT.US) to Buy Rating, Raises Target Price to $9
Moomoo NewsMar 21 07:33 ET · Ratings
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8
MT NewswiresMar 21 07:16 ET · Ratings
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March
Yahoo FinanceMar 20 15:06 ET
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsMar 18 07:31 ET · Ratings
Adaptive Biotechnologies (ADPT) Gets a Buy From BTIG
TipRanksMar 18 05:58 ET · Ratings

Comments

This_Guy

Dec 9, 2024 07:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

1

This_Guy

Dec 9, 2024 07:27

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Positive
Phase 3 trial data shows clonoSEQ can help avoid unnecessary transplantation procedures in MCL patients
FELIX study demonstrated 84% treatment response rate with MRD <10⁻⁶
Evidence supports clonoSEQ's effectiveness in early detection of disease progression
Data validates test'...

3

Jaguar8

Dec 9, 2024 06:19

NEWS SATURDAY 12/7

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies (ADPT) presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® test in measuring residual disease (MRD) for blood cancer treatment. Key findings from multiple studies demonstrate that achieving MRD lev...

1

Jaguar8

Aug 29, 2024 20:03

NEWS

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...

2

RiskGame

Jun 29, 2024 07:55

Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.

3

ADPT Adaptive Biotechnologies

Trade Overview

Capital Trend

News

Comments

Market Insights